Sort   by:  
 Page size 
UnknownEffect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Not available
S-EPMC4979167 | biostudies-literature
UnknownEfficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
Not available
S-EPMC3856961 | biostudies-literature
UnknownSensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.
Not available
S-EPMC8274402 | biostudies-literature
UnknownEfficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Not available
S-EPMC4380721 | biostudies-literature
UnknownDivergent mutational processes distinguish hypoxic and normoxic tumours.
Not available
S-EPMC7002770 | biostudies-literature
UnknownAdding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Not available
S-EPMC7616360 | biostudies-literature
UnknownDuration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Not available
S-EPMC7616389 | biostudies-literature
UnknownEvidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.
Not available
S-EPMC4321900 | biostudies-literature
UnknownCopy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.
Not available
S-EPMC9949586 | biostudies-literature
UnknownShared heritability and functional enrichment across six solid cancers.
Not available
S-EPMC6347624 | biostudies-literature
Sort   by:  
 Page size